-
Product Insights
NewOcular Melanoma – Drugs In Development, 2024
Empower your strategies with our Ocular Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body The Ocular...
-
Product Insights
NewRhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy,...
-
Product Insights
NewPlaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024
Empower your strategies with our Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 report and make more profitable business decisions. Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a...
-
Product Insights
NewNeuroblastoma – Drugs In Development, 2024
Empower your strategies with our Neuroblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands before spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include a lump in the abdomen or chest, weakness, bone pain, breathing problems, dark...
-
Product Insights
NewNeuroendocrine Cancer – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Cancer – Drugs In Development, 2024 report and make more profitable business decisions. A neuroendocrine cancer, often referred as a neuroendocrine tumor (NET) or neuroendocrine neoplasm, begins in the specialized cells of the body’s neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and help control many of the body’s functions. Hormones are chemical substances that are carried through the bloodstream to have...
-
Product Insights
NewUveal Melanoma – Drugs In Development, 2024
Empower your strategies with our Uveal Melanoma – Drugs In Development, 2024 report and make more profitable business decisions. Uveal melanoma, the most common intraocular tumor, is a disease in which malignant (cancer) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include a dark spot on the iris, glaucoma, eye pain, and eye redness. Uveal melanoma is more common...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPYK-04 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SPYK-04 in Ovarian Cancer Drug Details: SPYK-04 is under development for the treatment of advanced...